US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

34.42

+0.13980.41%

Volume:3K

Turnover:109.54K

Market Cap:13.77M

PE:- -

High:34.47

Open:34.47

Low:34.15

Close:34.28

52wk High:34.86

52wk Low:25.79

Shares:400.00K

Float Shares:400.00K

Volume Ratio:2.61

T/O Rate:0.80%

Dividend:0.08

Dividend Rate:0.24%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Johnson & Johnson Schedules Investor Call to Discuss Third-Quarter Results

Biogen, Eisai announce positive recommendation for Leqembi in Canada

Eisai: Canada's Drug Agency Issues Final Positive Recommendation for Leqembi Reimbursement in Early Alzheimer's Disease

THOMSON REUTERS

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

MT Newswires Live

GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator

CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff

OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China

ABBISKO-B Initiates First Patient Dosing in Phase I Trial for Novel Pan-KRAS Inhibitor

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

Trinity Biotech Advances Diagnostics Transformation as Nasdaq Compliance Pressure Mounts

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

US FDA - Approves Stelara for Pediatric Ulcerative Colitis

THOMSON REUTERS

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Edwards Lifesciences CVP Emeacla Annette Bruls Sells 2,644 Shares Worth $237,903.12

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BMED/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":34.42,"timestamp":1788465600000,"preClose":34.2802,"halted":0,"volume":3201,"delay":0,"changeRate":0.0040781559034078286,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"Pre-Mkt","change":0.1398,"latestTime":"09-04 06:38:02 EDT","open":34.47,"high":34.47,"low":34.15,"amount":109541,"amplitude":0.009335,"askPrice":54.72,"askSize":100,"bidPrice":27.95,"bidSize":50,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":34.42,"sharesOutstanding":360000,"nav":34.280916,"aum":13712366.4,"dividendRate":0.002362,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.42,"preClose":34.42,"latestTime":"16:18 EDT","volume":7,"amount":241.53,"timestamp":1788466684460,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.609652868720226,"impliedVol":0.2836,"impliedVolPercentile":0.7649},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.609652868720226,"shares":400000,"dividePrice":0.0813,"high":34.47,"amplitude":0.009335,"preClose":34.2802,"low":34.15,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":34.42,"committee":-0.333333,"eps":0,"divideRate":0.002362,"volume":3201,"delay":0,"ttmEps":0,"open":34.47,"prevYearClose":30.32,"prevWeekClose":33.8786,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":34.5006,"twentyDayClose":31.3112,"sixtyDayClose":28.6562},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664883779","title":"Johnson & Johnson Schedules Investor Call to Discuss Third-Quarter Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883779","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883779?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:07","pubTimestamp":1788210430,"startTime":"0","endTime":"0","summary":"Johnson & Johnson schedules investor call to discuss third-quarter resultsJohnson & Johnson schedules an investor conference call on fiscal third-quarter results for Oct. 13, 2026 at 8:30 a.m. ET.Earn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL3RsKfR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689605.HKD","JDOC","BK4007","LU0053666078.USD","IE0001KFT4U8.USD","IE00BVYPNV92.GBP","IE00B19Z3B42.SGD","LU0820561818.USD","LU0964807845.USD","TRUH","LU1066051225.USD","LU2756315318.SGD","LU0640476718.USD","XLV","LU2403377893.USD","IE00BKVL7J92.USD","LU0345769128.USD","MEDX","LU0210528500.USD","IE00B2B36J28.USD","LU1059921491.USD","VHT","JNJ","SG9999002224.SGD","LU0426417589.USD","FTXH","IXJ","LU1145028129.USD","LU0070217475.USD","RXL","IE00BLSP4239.USD","LU1732799900.SGD","IE00BSNM7G36.USD","IYH","IE00B7SZLL34.SGD","GDOC","PJP","IHE","IE00BDGV0183.EUR","LU1043141123.HKD","LU1929549753.HKD","LU1074936037.SGD","LU2023250330.USD","IE000BZT7R73.USD","BK4534","LU1162221912.USD","LU0320765646.SGD","BMED","FHLC","LU0912757837.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000087","title":"Biogen, Eisai announce positive recommendation for Leqembi in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000087","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000087?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:10","pubTimestamp":1788199810,"startTime":"0","endTime":"0","summary":"Eisai (ESAIY) and Biogen Canada (BIIB) announced receipt of the Canada’s Drug Agency’ final positive recommendation supporting public reimbursement...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announce-positive-recommendation-for-leqembi-in-canada-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announce-positive-recommendation-for-leqembi-in-canada-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BIIB","ESAIY","LU0320765992.SGD","BK4139","BK4588","BK4007","BMED","IE00B19Z9Z06.USD","LU0234570918.USD","LU0889565916.HKD","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0109394709.USD","BK4585","PBE","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664300705","title":"Eisai: Canada's Drug Agency Issues Final Positive Recommendation for Leqembi Reimbursement in Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2664300705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664300705?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:07","pubTimestamp":1788199651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","BIIB","LU0320765992.SGD","BK4139","BK4588","BMED","IE00B19Z9Z06.USD","LU0234570918.USD","LU0889565916.HKD","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0109394709.USD","BK4585","PBE","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663800423","title":"Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663800423","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663800423?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:29","pubTimestamp":1788190151,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics'  future growth will hinge more on its wholly owned programs than on its newly approved partner therapy, with the company's first clinical readouts from its proprietary pipeline expected in H1 2027. Wedbush Securities said Monday in a report.Wedbush highlighted PN-8047, an oral version of rusfertide, a treatment recently approved for polycythemia vera and commercialized by Takeda Pharmaceutical . PN-8047 appears similarly potent and may move into a phase 2 study in 2027 if early safety and iron-lowering data are positive, the report said.Protagonist's cash position is strengthened by payments tied to rusfertide's regulatory approval, including a $200 million opt-out fee and a $75 million milestone, along with similar payments from Johnson & Johnson  for icotyde, an oral anti-inflammatory drug being developed for psoriasis and other immune conditions, the report said.Wedbush maintained its outperform rating on Protagonist stock with a $173 price target.Price: 14","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1430594728.SGD","TRUH","LU1032466523.USD","RXL","FHLC","FTXH","LU1585245621.USD","LU1894683264.USD","SG9999013999.USD","LU0432979614.USD","LU1244550494.USD","GDOC","LU2750360641.GBP","LU0234572021.USD","PTGX","IXJ","JDOC","SG9999002232.USD","IE00BFTCPJ56.SGD","LU2347655156.SGD","IE0034235303.USD","VHT","IE00BDGV0183.EUR","LU0122379950.USD","LU2430703178.SGD","LU0320765646.SGD","TAK","XLV","BMED","LU1196500208.SGD","IHE","JNJ","LU0426412945.USD","IE00BLSP4452.SGD","PJP","SG9999001176.SGD","MEDX","LU1074936037.SGD","LU1221951046.USD","LU1145028129.USD","IE000SO60NU8.SGD","LU2602419157.SGD","LU0795875169.SGD","BK4139","IYH","LU2430703251.USD","IE0002270589.USD","IE000BZT7R73.USD","SGXZ57979304.SGD","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113021196","title":"GenSci161 Injection Clinical Trial Application of Changchun High-Tech Subsidiary Accepted by Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1113021196","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113021196?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:28","pubTimestamp":1788179298,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) has announced that its majority-owned subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., recently received the official Acceptance...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0057","IBBQ","BK0239","BK0075","BK0188","000661","BK0028","IBBJ","BK0046","MDTX","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178504231","title":"CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff","url":"https://stock-news.laohu8.com/highlight/detail?id=1178504231","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178504231?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177626,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) has announced the official initiation of the first clinical trial site in China for its Phase 1 study of the SYH2092 injection, targeting weight management in adults who are...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1515","LU2039709279.SGD","LU1226287792.SGD","KURE","LU0314109678.HKD","LU1008478684.HKD","LU1226287875.USD","LU0880133367.SGD","LU0315179316.USD","IBBJ","LU1226288170.HKD","PSYK","LU1226287529.USD","LU1226288253.USD","LU1951186391.HKD","LU1807302812.USD","LU0067412154.USD","LU0140636845.USD","LU1813983027.USD","IBBQ","LU1993786604.SGD","BK1521","LU0072913022.USD","MDTX","01093","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1960683339.HKD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1191","IE0008368742.USD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU1152091168.USD","LU1328277881.USD","IE0008369823.USD","SG9999004220.SGD","BMED","LU0501845795.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131581918","title":"OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1131581918","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131581918?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:28","pubTimestamp":1788172096,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has announced that the first patient has been enrolled in the Chinese Phase III clinical trial for OT-202, its investigational therapy for dry eye disease (DED). This milestone...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","MDTX","IBBJ","IBBQ","BMED","01477","BK1191","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185737367","title":"ABBISKO-B Initiates First Patient Dosing in Phase I Trial for Novel Pan-KRAS Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1185737367","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185737367?lang=en_us&edition=fundamental","pubTime":"2026-08-31 08:22","pubTimestamp":1788135744,"startTime":"0","endTime":"0","summary":"ABBISKO-B has announced that its subsidiary, Shanghai Abbisko Biopharmaceutical Co., Ltd., has completed the first patient dosing in a Phase I clinical trial for ABSK211, an oral, high-potency,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","PSYK","BMED","IE00B543WZ88.USD","IBBQ","LU2476274308.USD","LU2488822045.USD","LU2778985437.USD","LU2476274720.SGD","IBBJ","MDTX","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","FRTY","LABU","NVIB","TAK","PTGX","IBB","PINK","MRNY","GDOC","BK4007","PSCH","SYNB","IDNA","MEDI","BK4588","TBXU","RSPH","IEIH","BMED","BK4139","XLVX","MRNX","LFSC","GNMX","IYH","BK4585","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663043488","title":"Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2663043488","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663043488?lang=en_us&edition=fundamental","pubTime":"2026-08-30 07:30","pubTimestamp":1788046226,"startTime":"0","endTime":"0","summary":"Gilead Sciences stock has delivered very strong gains over the past few years, yet current valuation checks still suggest the shares screen as inexpensive on several metrics. The question for investors is how that strong track record and the latest product approvals align with a profile that continues to lean cheap.\n\nOver 5 years the stock has returned about 143%, which puts recent moves in the context of a long, powerful run that investors now need to judge against today’s pricing.\nThe...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-stays-cheap-after-a-143-five-year-run","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-stays-cheap-after-a-143-five-year-run","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2089984988.USD","LU1934455194.USD","LU1934455277.USD","MEDI","LU2468319806.SGD","BK4568","TBXU","BK4139","LU0289739699.SGD","BK4550","BK4578","LU0965508806.USD","IE00BKVL7J92.USD","IE00B3T34201.USD","BIB","LU0109394709.USD","LU1934455863.HKD","SG9999015978.USD","BK4585","IE00B19Z3B42.SGD","BK4532","LU1066051498.USD","BK4588","LU1839511570.USD","IBBQ","LU0823416689.USD","LU0234570918.USD","GILD","TMED","BBH","LU1066053197.SGD","BK4566","LU0058720904.USD","LU0965509283.SGD","SG9999015945.SGD","LU0965509010.AUD","LU2112291526.USD","IBB","LU1061106388.HKD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU0114720955.EUR","BMED","LU1585245621.USD","LU1023059063.AUD","LU1571399168.USD","LU0122379950.USD","LU0882574055.USD","LU2324357040.USD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019778","title":"Pharma Industry Stares Down Biggest Patent Cliff in Decades","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019778?lang=en_us&edition=fundamental","pubTime":"2026-08-29 09:00","pubTimestamp":1787965200,"startTime":"0","endTime":"0","summary":"Most companies sell a hit product for as long as customers want it. For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. B","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1941712264.USD","LU1814569148.SGD","LU0868494617.USD","ABBV","LU2756315318.SGD","LLYZ","LU1244550577.SGD","LU2023250843.SGD","IE00BK4W5M84.HKD","LU0417517546.SGD","LU0820562030.AUD","BK4532","IE0002141913.USD","LU0823434583.USD","LU0158827948.USD","IE00B3PB1722.GBP","LU0316494557.USD","SGXZ81514606.USD","LU2361045086.USD","LU1868837136.USD","LU2089284900.SGD","IE00B42XCP33.USD","SG9999015978.USD","IDNA","LU2087625088.SGD","LU0029864427.USD","LU0225284248.USD","LU1064131342.USD","LU1066051811.HKD","LU1551013425.SGD","LU2213496289.HKD","LU1670710588.SGD","LU1732800096.USD","LU0511384066.AUD","LU0823416689.USD","LU1989771016.USD","IE00B1BXHZ80.USD","LU0942090050.USD","LU1035773651.USD","PAWZ","LU2129689514.USD","LU0289739343.SGD","LU1003077747.HKD","LU2491050071.SGD","LU2491050154.USD","IE00BFXG1179.USD","LU1116320901.HKD","LU2360032135.SGD","LU1670711123.USD","LU1037948541.HKD","LU1280957306.USD","LU0472753341.HKD","LU2462591350.SGD","LU0861579265.USD","LU2211815571.USD","SG9999011175.SGD","FHLC","LU0256863811.USD","LU2456880835.USD","LU0061475181.USD","IE0001KFT4U8.USD","LU0648001328.SGD","SGXZ99366536.SGD","AGNG","LU0965509283.SGD","IE00BKDWB100.SGD","LU1934455194.USD","LU0943347566.SGD","LU1923622614.USD","IE00BFTCPJ56.SGD","MEDI","LU0708994859.HKD","SGXZ51526630.SGD","SG9999017495.SGD","LU1670711040.USD","NVOH","LU1430594728.SGD","LU2347655073.USD","LU1201861249.SGD","SGXZ57979304.SGD","LU2596442595.SGD","LU1035775433.USD","LU1074936037.SGD","LU0079474960.USD","LU0320765646.SGD","LU0353189763.USD","LU1496350171.SGD","LU0980610538.SGD","BK4139","IE00BVYPNV92.GBP","LU0234572021.USD","GB00BDT5M118.USD","LU1983299246.USD","IE00B19Z3581.USD","BK4501","IE00B4R5TH58.HKD","LU2360106947.USD","BK4588","LU0069063385.USD","LU1934455863.HKD","BMY","LU0114720955.EUR","BK4599","LU0320765489.SGD","LU0471298777.SGD","LU0211328371.USD","LU1145028129.USD","LU1267930573.SGD","LU1974910355.USD","NVOX","SG9999015986.USD","PJP","LGHT","LU2087621335.USD","IHE","LU0266013472.USD","LU0882574055.USD","LU2357627491.SGD","LU1989772840.SGD","PTH","LU0456855351.SGD","LU2347655156.SGD","HRTS","LU0820561818.USD","LU2552382132.HKD","LLYX","IE00B775H168.HKD","LU0965509101.SGD","BK4516","IE000MB6IJN5.SGD","LU0738911758.USD","LU1712237335.SGD","SG9999014914.USD","IE000SO60NU8.SGD","IE00BN8TJ469.HKD","SG9999014542.SGD","LU1699723380.USD","LU1032466523.USD","IE00BJT1NW94.SGD","LU0133085943.USD","MRNY","LU0109394709.USD","SG9999003800.SGD","ILDR","IE00B7KXQ091.USD","LU1929549753.HKD","LU2063271972.USD","LU1236620750.USD","LU1162221912.USD","LU1917777945.USD","LU0345770308.USD","IE00B19Z3B42.SGD","IE0004445015.USD","LU0203347892.USD","LU2028103732.USD","LU2242652126.USD","LU0237698245.USD","LU2168564065.EUR","LU2357305700.SGD","LU2361044865.SGD","LU1868837300.USD","GDOC","TMED","IE00BDGV0183.EUR","LU1934455277.USD","SGXZ31699556.SGD","LU1804176565.USD","LU0395794307.EUR","LU1691799644.USD","BK4566","LU1670627923.USD","LU0985481810.HKD","LU1093756168.USD","LU0912757837.SGD","LU1323610961.USD","LU1366192091.USD","LU0306806265.USD","LU0256863902.USD","LU2462157665.USD","BK4559","LU1261432733.SGD","LU2237443382.USD","LU0211327993.USD","LU2237443549.SGD","LU2756315664.SGD","LU2089283258.USD","LU0965508806.USD","SG9999014575.USD","IE00BJJMRY28.SGD","SG9999014559.SGD","LU1116320737.USD","LU0310799852.SGD","LU2023250330.USD","NVOC","LU2237443978.SGD","BK4007","LU0477156953.USD","LU2108987350.USD","SG9999015945.SGD","LU0128525929.USD","LU0466842654.USD","TRUH","SG9999014898.SGD","LU0889565916.HKD","LLY","IE00BLSP4452.SGD","LU0689472784.USD","LU1037948897.HKD","ELIL","SG9999002224.SGD","LU0170899867.USD","LU2271345857.HKD","LU0058720904.USD","SG9999013999.USD","LU0661504455.SGD","LU0823434740.USD","GNOM","IE00BFSS7M15.SGD","LU1244550494.USD","LU0203201768.USD","LU2468319806.SGD","LU2552382058.USD","LU0689626769.HKD","BMED","SG9999014906.USD","ELIS","LU0795875169.SGD","LU1988902786.USD","LU2168563687.JPY","LU0985320562.USD","LU0949170772.SGD","LU0265550359.USD","LU2168564222.USD","LU2471134879.HKD","LU0432979614.USD","LU1670710661.SGD","LU0345770993.USD","LU0211331839.USD","THNR","IE00BGHQF631.EUR","LU0726765562.USD","LU2125154778.USD","LU1093756325.SGD","SG9999014567.USD","LU2746668974.SGD","SG9999001176.USD","LU1066051225.USD","BBH","IE00BK4W5L77.USD","VHT","GLAM","IE0000B7K699.USD","LU0098860793.USD","IE0005OL40V9.USD","LU0238689110.USD","LU0683600562.USD","LU0070302665.USD","LU0289961442.SGD","IE00BFSS8Q28.SGD","MRNA","LU2129689605.HKD","LU0964807845.USD","LU1868836757.USD","IE00BWXC8680.SGD","LU1720051108.HKD","LU1069344957.HKD","IE00BVYPNW00.USD","LU0868494708.USD","LU0795875086.SGD","LU2237443622.USD","LU0234570918.USD","LU2324357040.USD","LU1066053197.SGD","LU1571399168.USD","MHIP","LU1868836914.USD","LU0267386448.USD","IE00BSNM7G36.USD","LU0786609619.USD","LU2023251221.USD","LU0354030438.USD","SG9999014880.SGD","CURE","LU0354030511.USD","LU0289739699.SGD","LU1623119135.USD","LU0265550946.USD","LU0320765992.SGD","LU2750360997.AUD","LU0385154629.USD","LU0174119429.USD","LU1979441026.SGD","LU1941712348.USD","LU0321505868.SGD","LU0310800379.SGD","LU2106854487.HKD","XLV","IE00BKVL7J92.USD","LU0320765059.SGD","LU0672654240.SGD","MEDX","LU0094547139.USD","LU1061106388.HKD","LU1267930730.SGD","LU2023250504.SGD","LU1839511570.USD","LU1718418525.SGD","LU1551013342.USD","LU1023059063.AUD","LU2129689431.USD","SG9999001176.SGD","SG9999015358.SGD","IE00BLSP4239.USD","LU0097036916.USD","IYH","LU2125154935.USD","LU0306807586.USD","IE00BKPKM429.USD","LU0006306889.USD","BK4533","IE00BBT3K403.USD","LU2168564149.EUR","LU0882574139.USD","IE0009355771.USD","LU0323591593.USD","JDOC","BK4551","LU1291159041.SGD","SG9999015952.SGD","OZEM","LU2471134952.CNY","LU0198837287.USD","LU1127390331.HKD","LU1069347547.HKD","IE000WAW04H5.SGD","WDNA","FTXH","MRK","RVMD","LU2433249047.HKD","LU0210536198.USD","LLII","LU0225771236.USD","LU0471298694.HKD","IE00BJJMRX11.SGD","LU2552382215.SGD","LU1629891620.HKD","IE00BN29S564.USD","LU1732799900.SGD","IE000BZT7R73.USD","LU0203202063.USD","BK4534","LU1066051498.USD","IE0002270589.USD","IE00BJLML261.HKD","LU0122379950.USD","IE00B1XK9C88.USD","LU1236620834.HKD","IE00BZ1G4Q59.USD","BK4585","LU0124676726.USD","BK4568","LU2417539215.USD","SG9999001440.SGD","LU1244550221.USD","LU2264538146.SGD","IE00B2B36J28.USD","LU2461242641.AUD","LU2896262040.SGD","LU1989772923.USD","LU0208291251.USD","LU2265009873.SGD","LU1868836591.USD","LU0820561909.HKD","LU0708995401.HKD","LU1548497426.USD","LU2242646821.SGD","LU0545039389.USD","LU2237443465.HKD","LU1670628061.USD","IE00BJJMRZ35.SGD","LU0130102774.USD","LU1267930490.SGD","LU0109391861.USD","LU2168564495.EUR","IE000M9KFDE8.USD","CANC","BK4548","LU0787776722.HKD","LU0057025933.USD","LU2471134523.USD","LU2491049909.HKD","SG9999018857.SGD","SG9999015341.SGD","IE00B4JS1V06.HKD","NVO","IE0004445239.USD","IXJ","SG9999002232.USD","PPH","RXL","LU1720051017.SGD","LU1496350502.SGD","LU0106261372.USD","LU0096364046.USD","LU0225283273.USD","BK4550","LU1883839398.USD","LU0640476718.USD","LU1232071149.USD","LU2471134796.USD","LU2111349929.HKD","LU2237443895.HKD","MRNX","LU0553294199.USD","LU2750360641.GBP","LU1585245621.USD","LU2112291526.USD","LU2602419157.SGD","LU0321505439.SGD","LU0965509010.AUD","LU2361044949.HKD","LU0158827781.USD","LU2089984988.USD","LU2125909593.SGD","IE0009354923.USD","LU0353189680.USD","LU2133065610.SGD","LU2125909247.SGD","SG9999018865.SGD","LU2237438978.USD","LU2236285917.USD","LU0130517989.USD","LU0859254822.USD","LU1057294990.SGD","LU2746668461.USD","LU0154236417.USD","IE000F7OJYX1.SGD","BK4581","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","PINK","IYH","BMED","MEDI","BK4588","IDNA","FRTY","RSPH","BBP","IBB","MRNY","LABU","IEIH","MRNX","TBXU","GNMX","NVIB","BK4585","SYNB","GDOC","LFSC","TECB","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","RSPH","LFSC","IBB","PINK","MEDI","BBP","SYNB","TAK","GDOC","BK4588","MRNX","LABU","IYH","TBXU","XLVX","FRTY","IEIH","MRNY","TECB","GNMX","BK4007","BMED","IDNA","PSCH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016663","title":"Trinity Biotech Advances Diagnostics Transformation as Nasdaq Compliance Pressure Mounts","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016663?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:47","pubTimestamp":1787953648,"startTime":"0","endTime":"0","summary":"Trinity Biotech ( ($TRIB) ) has shared an announcement. On August 28, 2026, Trinity Biotech reported progress in its diagnostics business, highligh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/trinity-biotech-advances-diagnostics-transformation-as-nasdaq-compliance-pressure-mounts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/trinity-biotech-advances-diagnostics-transformation-as-nasdaq-compliance-pressure-mounts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XBI","TRN","NQmain","BK4149","BK4588","BMED","BK4585","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663401575","title":"Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2663401575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663401575?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:28","pubTimestamp":1787952480,"startTime":"0","endTime":"0","summary":"DJ Perrigo Co. PLC Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Perrigo Co. PLC  advanced 2.84% to $14.48 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.25% to 7,711.76 and Dow Jones Industrial Average  falling 0.02% to 53,559.99.Perrigo Co. PLC closed 39.62% below its 52-week high of $23.98, which the company reached on August 28th.The stock outperformed some of its competitors Friday, as Johnson & Johnson  rose 0.85% to $268.04, Procter & Gamble Co.  rose 0.45% to $143.78, and Abbott Laboratories  rose 0.79% to $112.47.Trading volume  remained 805,910 below its 50-day average volume of 3.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 28, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRUO","PJP","JDOC","LU0912757837.SGD","TRUH","IE000MB6IJN5.SGD","BK4534","IE00B19Z3581.USD","IE00BKDWB100.SGD","LU0237698245.USD","XLV","LU1228905540.USD","BMED","TMED","LU1721429402.USD","LU1267930813.SGD","FSTA","LU0289739699.SGD","ABT","IXJ","IHI","LU1244550221.USD","IE00BVYPNV92.GBP","IE00B4R5TH58.HKD","LU1629891620.HKD","PRGO","LU1721429741.USD","LU0122379950.USD","PG","LU1228905037.USD","UGE","VHT","FTXH","GDOC","RXL","LU0432979614.USD","SG9999013999.USD","SG9999014559.SGD","MEDX","IYH","LU1032466523.USD","IE00BLSP4452.SGD","JNJ","LU0795875086.SGD","SG9999014567.USD","LU0792757196.USD","FHLC","SGXZ57979304.SGD","XLP","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663088015","title":"Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2663088015","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663088015?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:15","pubTimestamp":1787951700,"startTime":"0","endTime":"0","summary":"- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress  - PrePsia patent portfolio expands to nine granted U.S. and European patents  - Company issues ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/28/3352900/8624/en/trinity-biotech-provides-diagnostics-business-transformation-and-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4082","BMED","EES","BK4588","LCLG","TRN","TRIB","XBI","BK4149","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663601596","title":"US FDA - Approves Stelara for Pediatric Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2663601596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663601596?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:00","pubTimestamp":1787950849,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0203345920.USD","LU0820561909.HKD","SGXZ57979304.SGD","LU0432979614.USD","JNJ","LU0964807845.USD","FTXH","VHT","SGXZ80539844.SGD","LU0683600562.USD","SG9999002224.SGD","IXJ","TRUH","LU1280957306.USD","LU1261432733.SGD","LU2089984988.USD","BK4585","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0545562505.USD","LU0943347566.SGD","LU2133065610.SGD","LU2750360641.GBP","LU1228905540.USD","PJP","LU2756315318.SGD","LU0058720904.USD","BMED","MEDX","LU1244550494.USD","LU1023059063.AUD","LU1894683264.USD","BK4504","GDOC","IE00BVYPNV92.GBP","LU1145028129.USD","RXL","IE0001KFT4U8.USD","LU1674673691.USD","FHLC","JDOC","IE000SO60NU8.SGD","BK4532","XLV","IYH","LU2756315664.SGD","LU2592432038.USD","LU1162221912.USD","IHE","LU1244550577.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663613015","title":"Biogen Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663613015","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663613015?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:57","pubTimestamp":1787950620,"startTime":"0","endTime":"0","summary":"DJ Biogen Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Biogen Inc.  shed 1.35% to $218.50 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.25% to 7,711.76 and Dow Jones Industrial Average  falling 0.02% to 53,559.99.The stock's fall snapped a five-day winning streak.Biogen Inc. closed 1.95% short of its 52-week high of $222.85, which the company achieved on August 25th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  rose 0.85% to $268.04, Pfizer Inc.  fell 0.21% to $27.96, and AbbVie Inc.  fell 1.03% to $255.48.Trading volume  remained 667,372 below its 50-day average volume of 1.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 28, 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","BK4532","BK4585","LU0109394709.USD","BK4139","LU0889565916.HKD","BIIB","IE00B19Z9P08.USD","BK4533","BK4588","IE00B19Z9Z06.USD","LU0320765992.SGD","PBE","IE00B894F039.SGD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663701587","title":"Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663701587?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:35","pubTimestamp":1787949300,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slid 2.14% to $145.68 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.25% to 7,711.76 and Dow Jones Industrial Average  falling 0.02% to 53,559.99.Gilead Sciences Inc. closed 7.38% short of its 52-week high of $157.29, which the company achieved on February 11th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  rose 0.85% to $268.04, Pfizer Inc.  fell 0.21% to $27.96, and Abbott Laboratories  rose 0.79% to $112.47.Trading volume  remained 3.2 million below its 50-day average volume of 7.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 28, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4585","LU0234570918.USD","LU0965509283.SGD","LU0965509101.SGD","IBBQ","LU1057294990.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU1674673691.USD","BK4583","TMED","BK4550","IE00B3T34201.USD","GILD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU1066051498.USD","LU1839511570.USD","IE0002270589.USD","LU1934455277.USD","LU2357627491.SGD","LU1934455863.HKD","LU2112291526.USD","LU1674673428.USD","TBXU","LU0289739699.SGD","LU0882574055.USD","LU2089984988.USD","LU2468319806.SGD","BK4578","LU1037948897.HKD","LU1066053197.SGD","LU1778281490.HKD","LU1934455194.USD","SG9999015978.USD","BK4139","LU1585245621.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","SG9999015945.SGD","IBB","LU0122379950.USD","BK4532","LU1037948541.HKD","LU0861579265.USD","LU1061106388.HKD","LU0823416689.USD","LU2087621335.USD","IE00BKVL7J92.USD","LU0889565916.HKD","BIB","LU2324357040.USD","IE00BSNM7G36.USD","SG9999015952.SGD","LU0320765992.SGD","LU0965508806.USD","SG9999015986.USD","BK4588","LU0058720904.USD","MEDI","LU1023059063.AUD","LU0109394709.USD","BMED","BK4568","LU0859254822.USD","LU1430594728.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013044","title":"Edwards Lifesciences CVP Emeacla Annette Bruls Sells 2,644 Shares Worth $237,903.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013044","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013044?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:33","pubTimestamp":1787949220,"startTime":"0","endTime":"0","summary":"Edwards Lifesciences CVP EMEACLA Annette Bruls sells 2,644 shares worth $237,903.12Edwards Lifesciences officer Annette Bruls, CVP, EMEACLA, sold 2,644 common shares on Aug. 28, 2026 at $89.98.Directl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL8xz2jT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Edwards Lifesciences CVP Emeacla Annette Bruls Sells 2,644 Shares Worth $237,903.12","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IE00BFXG0V08.USD","BK4504","BK4588","SG9999001176.SGD","IE00BN0W2V16.EUR","SGXZ57979304.SGD","BK4585","IE00BN0W2W23.USD","SG9999001176.USD","IE00BYQQ9H92.USD","LU0289739699.SGD","LU0823416689.USD","LU0058720904.USD","AGNG","SG9999013999.USD","LU0345774631.USD","EW","BMED","BK4567","IE00BN0W2T93.GBP","IHI","LU0345774391.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}